Cencora (NYSE:COR) Share Price Crosses Above Two Hundred Day Moving Average of $226.12

Cencora, Inc. (NYSE:COR) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $226.12 and traded as high as $235.07. Cencora shares last traded at $234.70, with a volume of 985,762 shares traded.

Analyst Ratings Changes

Several research firms recently weighed in on COR. Citigroup increased their price objective on shares of Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Robert W. Baird upped their target price on shares of Cencora from $275.00 to $277.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. SVB Leerink started coverage on shares of Cencora in a research report on Monday, February 26th. They issued an “outperform” rating and a $261.00 target price for the company. StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of Cencora in a report on Monday, February 26th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average target price of $233.90.

Cencora Stock Up 0.9 %

The stock has a market capitalization of $46.81 billion, a P/E ratio of 25.68, a PEG ratio of 1.62 and a beta of 0.48. The company has a debt-to-equity ratio of 3.41, a current ratio of 0.89 and a quick ratio of 0.53. The stock’s fifty day moving average is $229.49 and its two-hundred day moving average is $226.12.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, topping analysts’ consensus estimates of $3.65 by $0.15. The firm had revenue of $68.41 billion during the quarter, compared to analysts’ expectations of $70.60 billion. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the firm posted $3.50 earnings per share. As a group, research analysts predict that Cencora, Inc. will post 13.44 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, May 24th. Investors of record on Friday, May 10th were given a $0.51 dividend. The ex-dividend date was Thursday, May 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.87%. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Insider Activity at Cencora

In related news, Director Dermot Mark Durcan bought 500 shares of the business’s stock in a transaction on Friday, May 24th. The stock was bought at an average price of $218.58 per share, for a total transaction of $109,290.00. Following the transaction, the director now directly owns 21,876 shares in the company, valued at $4,781,656.08. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Cencora news, Director Dermot Mark Durcan purchased 500 shares of the business’s stock in a transaction dated Friday, May 24th. The shares were acquired at an average price of $218.58 per share, for a total transaction of $109,290.00. Following the acquisition, the director now owns 21,876 shares of the company’s stock, valued at $4,781,656.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Robert P. Mauch sold 57,564 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $235.09, for a total transaction of $13,532,720.76. Following the transaction, the chief operating officer now owns 24,412 shares in the company, valued at approximately $5,739,017.08. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,956,675 shares of company stock worth $422,352,056. 15.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. acquired a new position in Cencora in the 4th quarter valued at $4,212,508,000. Price T Rowe Associates Inc. MD bought a new position in shares of Cencora during the 1st quarter worth about $2,183,619,000. JPMorgan Chase & Co. bought a new position in shares of Cencora during the 1st quarter worth about $1,199,695,000. Boston Partners bought a new position in shares of Cencora during the 1st quarter worth about $1,001,269,000. Finally, Capital Research Global Investors bought a new position in shares of Cencora during the 1st quarter worth about $650,424,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.